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Abstract
Background: Succinate dehydrogenase (SDH) has been associated with carcinogenesis in pheochromocytoma and 
paraganglioma. In the present study we investigated components of the oxidative phosphorylation system in human 
neuroblastoma tissue samples.
Methods: Spectrophotometric measurements, immunohistochemical analysis and Western blot analysis were used to 
characterize the aerobic mitochondrial energy metabolism in neuroblastomas (NB).
Results: Compared to mitochondrial citrate synthase, SDH activity was severely reduced in NB (n = 14) versus kidney 
tissue. However no pathogenic mutations could be identified in any of the four subunits of SDH. Furthermore, no 
genetic alterations could be identified in the two novel SDH assembly factors SDHAF1 and SDH5. Alterations in genes 
encoding nfs-1, frataxin and isd-11 that could lead to a diminished SDH activity have not been detected in NB.
Conclusion: Because downregulation of other complexes of the oxidative phosphorylation system was also observed, 
a more generalized reduction of mitochondrial respiration seems to be present in neuroblastoma in contrast to the 
single enzyme defect found in hereditary pheochromocytomas.
Background
According to the International Neuroblastoma (NB)
Pathology Classification, NBs are defined as embryonal
tumors of the sympathetic nervous system, derive from
the neural crest and arise in the adrenal medulla, paraver-
tebral sympathetic ganglia, and sympathetic paraganglia
[1]. Paraganglioma and pheochromocytoma are histolog-
ically related to NB as they are all neural crest derived.
NBs mainly consist of immature neuroblasts, whereas
pheochromocytomas and paragangliomas contain
mature chromaffin cells.
Pheochromocytomas and paragangliomas frequently
exhibit mutations in the succinate dehydrogenase (SDH)
subunits SDHB, SDHC, SDHD indicating that these SDH
subunits act as tumor suppressors in neuroendocrine tis-
sues [2]. The SDH complex is composed of four subunits
and contains a flavin molecule (FAD), non-heme iron
centers and a b-type cytochrome as prosthetic groups.
The complex is anchored by a large SDHC and a small
SDHD subunit that together comprise the membrane-
spanning heme protein cyt b [3]. In addition, two assem-
bly factors of SDH SDHAF1 and SDH5 have been
reported recently. SDH5 is a gene required for flavination
of SDH [4]. Pathogenic mutations in SDH5 have been
identified in paragangliomas [5].
Mutations in the PHOX2B and anaplastic lymphoma
kinase (ALK) genes are linked to a predisposition for neu-
roblastoma [6-10]. Mutations in PHOX2B have been
found in a minority of familial neuroblastoma cases. So
far no clear link to the energy metabolism has been dem-
onstrated for these two genes.
Mutations in the VHL gene cause von Hippel-Lindau
disease, a dominantly inherited familial cancer syndrome
predisposing to a variety of malignant and benign neo-
plasms, including clear cell renal carcinoma and pheo-
chromocytoma [11-13]. Loss of VHL protein in tumors
results in an accumulation of hypoxia-inducible factor-1α
(HIF-1α) during normoxia. Such accumulation of HIF-1α
in turn induces expression of various genes containing
hypoxia-responsive elements, thereby decreasing the
expression of components of aerobic energy metabolism
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[14-17]. Accordingly, not only is SDHB protein sup-
pressed in tumors with mutations in SDHB and SDHD,
but also in a subset of tumors with VHL mutations which
act through HIF1α [18,19]. In addition, alterations of pro-
teins involved in Fe-S cluster biogenesis, including Nitro-
gen fixation-1 homolog (nfs-1), LYR motif containing 4
(LYRM4; isd11), and frataxin, can lead to a reduction of
SDH activity [20-24]. For example, disrupted expression
of frataxin in murine hepatocytes causes decreased oxi-
dative phosphorylation (OXPHOS) paralleled by reduced
activity of iron-sulfur cluster-containing proteins [20].
During the process of OXPHOS ATP is formed as elec-
trons are transferred from NADH or FADH2 to molecu-
l a r  o x y g e n  ( O 2 )  b y  a  s e r i e s  o f  e l e c t r o n  c a r r i e r s .  T h e
energy released by catabolic biochemical processes, such
as glycolysis, citric acid cycle, and fatty acid oxidation is
stored as the reduced coenzymes NADH or FADH2.
There is a step by step transfer of electrons from NADH
or FADH2 to specific protein complexes, which are part
of the electron transport chain. Electrons are transferred
from these reduced equivalents, through the electron
transport chain (ETC), to O2. The ETC consists of four
multisubunit complexes namely complex I - IV. SDH is
both part of the ETC as well as the citric acid cycle. The
liberated energy is used to create a proton gradient over
the inner mitochondrial membrane. In the final reaction
of OXPHOS, the reflux of protons is used by the complex
V (ATP synthase) to produce ATP.
The aerobic use of glucose as an energy source through
glycolysis is a feature common to most solid tumors, in
turn leading to a lesser dependence on OXPHOS, which
is called the Warburg effect [25,26]. The downregulation
of OXPHOS in tumor cells seems to be achieved by dif-
ferent mechanisms. First, profound hypoxia can be the
cause of compensatory upregulation of glycolysis in most
tumors. Secondly, it is becoming more and more evident
that the loss of tumor suppressor genes such as VHL and
p53 or activation of oncogenes results in downregulation
of OXPHOS [27,28]. Finally, direct inactivation of com-
ponents of OXPHOS has been detected in a minority of
tumors. Besides the association of SDH and tumor devel-
opment, loss of NADH: ubiquinone oxidoreductase
(complex I) of the respiratory chain has also been shown
in oxiphilic tumors [29,30].
The aim of the present study was to determine if there
are specific alterations of aerobic energy metabolism in
NBs, especially of SDH, or if there is an overall downreg-
ulation of OXPHOS complexes.
Although it is generally accepted that solid cancers
exhibit in most cases a shift from oxidative phosphoryla-
tion to glycolysis the type of alteration has not been
investigated in many types of cancers, and to our knowl-
edge not in neuroblastic tumors.
Methods
Samples
NBs from 14 patients were obtained from the University
Hospital Salzburg, Austria and the Olga Hospital, Stutt-
gart, Germany. Fifteen unaffected kidney tissues served
as references for enzymatic measurements. For immuno-
histochemical studies formalin fixed, paraffin embedded
NBs and unaffected adrenal tissues were used.
The study was performed according to the Austrian
Gene Technology Act. Experiments were performed in
accordance with the Helsinki declaration of 1975 (revised
1983) and the guidelines of the Salzburg State Ethics
Research Committee (ethical agreement: AZ 209-11-E1/
823-2006) being no clinical drug trial or epidemiological
investigation. All patients have signed an informed con-
sent concerning the surgical removal and therapy of the
tumors. Furthermore the study did not extend to exami-
nation of individual case records. The anonymity of the
patients has been ensured.
All tissues were frozen and stored in liquid nitrogen
within 30 min after surgery. Tumor cell content and cellu-
lar composition of samples were evaluated using hema-
toxylin-eosin-stained frozen sections. Tissue samples
with a tumor cell content of over 90% were investigated.
Poorly differentiated or undifferentiated tumor tissues
were used in the study (Table 1).
Enzyme measurements
NB and kidney tissues (20-100 mg) were homogenized
with a tissue disintegrator (Ultraturrax, IKA, Staufen,
Germany) in extraction buffer (20 mM Tris-HCl, pH 7.6,
250 mM sucrose, 40 mM KCl, 2 mM EGTA) and finally
homogenized with a motor-driven Teflon-glass homoge-
nizer (Potter S, Braun, Melsungen, Germany). The homo-
genate was centrifuged at 600 g for 10 min at 4°C. The
postnuclear supernatant (600 g homogenate) containing
the mitochondrial fraction was used for measurement of
enzyme activities and Western blot analysis. Citrate syn-
thase was determined according to Srere [31] with modi-
fications. Briefly, the reaction mixture contained 50 mM
Tris-HCl pH 8.1, 0.1% bovine serum albumin (BSA), 0.1%
TritonX-100, 0.2 mM 5,5'-dithio-bis(2-nitrobenzoic acid),
0.15 mM acetyl-CoA and the 600 g homogenate. After
initially recording thiolase activity for 2 min the citrate
synthase reaction was started by addition of 0.5 mM
oxaloacetate and was followed at 412 nm for 8 min. The
mean unspecific thiolase activity in NBs was 2% of the CS
activity.
Enzyme activities of the OXPHOS complexes were
determined as previously described [32,33]. Briefly, rote-
none-sensitive complex I activity was measured spectro-
photometrically as NADH/decylubiquinone
oxidoreductase at 340 nm. The enzyme activities of cit-
rate synthase and complex IV (ferrocytochrome c/oxygenFeichtinger et al. BMC Cancer 2010, 10:149
http://www.biomedcentral.com/1471-2407/10/149
Page 3 of 9
oxidoreductase), and the oligomycin-sensitive ATPase
activity of the F1F0 ATP synthase were determined by
using buffer conditions as previously described by Rustin
et al. (1994) [34]. The whole reaction mixture for the
ATPase activity measurement was treated for 10 seconds
with an ultra-sonifier (Bio cell disruptor 250, Branson,
Vienna, Austria). SDH activity was measured according
to Rustin et al. with the following modifications. The
reaction mixture contained 50 mM potassium phosphate
pH 7.8, 2 mM EDTA, 0.1% BSA, 3 μM rotenone, 80 μM
2,6-dichlorophenol, 50 μM decylubiquinone, 1 μM anti-
mycin A, 0.2 mM ATP, 0.3 mM KCN and the 600 g
homogenate. The mixture was preincubated for 10 min at
37°C, started by addition of 10 mM succinate, and fol-
lowed for 6 min at 600 nm.
The reaction mixture for the measurement of the com-
plex III activity contained 50 mM potassium phosphate
buffer pH 7.8, 2 mM EDTA pH 8.6, 0.3 mM KCN, 100 μM
cytochrome c, 200 μM reduced decyl-ubiquinol. The
reaction was started by addition of the 600 g homogenate.
After 3 - 4 min the reaction was inhibited by addition of 1
μM antimycin A. Antimycin A- insensitive activity was
substracted from total activity to calculate complex III
activity. All spectrophotometric measurements (Uvicon
922, Kontron, Milan, Italy) were performed at 37°C.
Sequencing of SDHA, SDHB, SDHC, SDHD, SDHAF1, SDH5, 
nfs-1, LYRM4, frataxin, PHOX2B and ALK
DNA was isolated using a NucleoSpin® Tissue Kit (Mach-
erey-Nagel). RNA was isolated from cryosections of NB
tissues using Tri-Reagent™ (Molecular Research Center
Inc., Cincinnati, OH). 2 μg of RNA were treated with
DNase I (Ambion, Austin, TX) and reverse-transcribed
with 140 U Superscript II reverse transcriptase (Invitro-
gen Corporation, Carlsbad, CA) according to the manu-
facturer's instructions. 100 ng genomic DNA (for
sequencing of SDHB, SDHC, SDHD, SDHAF1, SDH5,
PHOX2B) or cDNA (for sequencing of SDHA, frataxin,
nfs1, LYRM4, ALK) were used for the PCR amplification
(Table 2). PCR products were incubated with Exo SAP IT
500 (USB Corporation), and the CEQ DTCS Quickstart
Kit (Beckman Coulter) was used for the sequencing reac-
tion using the PCR primers listed in Table 2, followed by
separation with a CEQ 2000 DNA Analysis System (Beck-
man Coulter).
Determination of the mtDNA copy number
The mtDNA copy number was determined as previously
described [35].
Western blot analysis
600 g homogenates were used for Western blot analysis.
After protein quantification (Pierce BCA Protein Assay),
a total of 5 μg protein was separated on 10% acrylamide/
bisacrylamide gels and transferred to nitrocellulose mem-
branes (Amersham Biosciences; Hybond™-C Extra) using
a CAPS buffer (10 mM 3-[cyclohexylamino]-1-propane
sulfonic acid, pH 11; 10% methanol). The membranes
were washed in Tris-buffered saline buffer (TBS, pH 7.4)
for 5 min, air-dried for 30 min, washed 10 min in TBS and
Table 1: Clinical characteristics of neuroblastoma patients and tumor tissues.




n-myc 1p del ploidy PHOX2B ALK
1 F 31 4 u.d. neg neg 2n neg n.c.
2 M 3 2A u.d. neg neg 3n neg n.c.
3 M 3 4S u.d. neg neg 3n neg n.c.
4 M 11 1 u.d. neg neg 3n neg n.c.
5 M 11 2B u.d. pos pos 3n/4n neg n.c.
6 M 15 2B u.d. neg neg 3n neg n.c.
7 F 142 4 u.d. neg neg 3n neg neg
8 F 1 3 u.d. neg neg 3n neg neg
9 M 7 3A u.d. neg neg 3n neg n.c.
10 F 10 4S p.d. neg neg 2n neg n.c.
11 M 11 1 u.d. neg n.d. n.d. neg neg
12 F 166 4 u.d. neg neg 3n neg neg
13 M 2 1 u.d. neg neg n.d neg n.c.
14 M 5 1 u.d. neg neg 3n neg n.c.
u.d.: undifferentiated; p.d.: poorly differentiated; n.d.: not determined; n-myc neg: no n-myc amplification; n-myc pos: n-myc amplification; 
PHO2B neg: no mutation; ALK neg: no ALK mutation, n.c.: no cDNA availableFeichtinger et al. BMC Cancer 2010, 10:149
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Table 2: Primers used for PCR and sequencing.
forward primer 5'-3' reverse primer 5'-3' bp Ref-sequ.
SDHA fragment 1* GCGAAGGACCTGGCGTCTA CCCAGAGTGCAGAAGCGTAT 1100 NM_004168.2
SDHA fragment 2 GACTGCGCGGCGGCAACA CAGCCTCTTCCTTCTCGGAT 1094 NM_004168.2
SDHB Exon 1 GGGTCCTCAGTGGATGTAGGCT GCCTTGCCCTATGCTTCCTC 272 NM_003000.2
SDHB Exon 2 GAATGCCTGCCTTTTCTAAGAAGA GCCATCGGATGATCTCAGATTTT 377 NM_003000.2
SDHB Exon 3 CCTGAGAAGACCAAATGGATAAGC AGCTGCAGCTGTTTTCCAGATG 300 NM_003000.2
SDHB Exon 4 TGTTGCATGTCAGTGCTGCCC GGTCCTCCTCCTGCCATAATATAGG 423 NM_003000.2
SDHB Exon 5 CGAGTAGTCAGTGTCCAAGAAATGG AATGGCTTGCATCAGCTTATGTTC 317 NM_003000.2
SDHB Exon 6 TTTGTTCATGCACTGACCCCA AAACCAGGCCCCTCAGAATG 307 NM_003000.2
SDHB Exon 7 TGAATTCCCTTTCCTCTGCACTC ATGACTAGGGTTGCTCTCTGCCA 323 NM_003000.2
SDHB Exon 8 TTGCTTGGACACTGAACCAGCT GCTGTATTCATGGAAAACCAAGATC 286 NM_003000.2
SDHC Exon 1 GCGTCACTTCCGTCCAGACC CTGCCCAGGCACAGGATAAA 150 NM_003001..3
SDHC Exon 2 CCCTTCACCCCTAAAAATAGAGAAG AAAATAATCTCCAGGGCCGGG 480 NM_003001..3
SDHC Exon 3 CCTGGCTTGGTATTGCAAAATATTG AAGGGTTCACCTCATCTACATAGCA 336 NM_003001..3
SDHC Exon 4 ACCTATTCAGGAGAATTGCTTGGA ATCAAGTGCTGAGTTTCAAAGGAGG 382 NM_003001..3
SDHC Exon 5 TGGTTTAGAATTGTATGAGGTGCCA GCGAGACTCCACTCTTGGGAA 387 NM_003001..3
SDHC Exon 6 CGCTTTTCTCTAGAATCATGCTGAG TCTACTGCTCCAAGGAGATCTGAAA 375 NM_003001..3
SDHD Exon 1 CCAGCATTTCCTCTTCCCTGTT CTCCTCAAGAGATCTCCCACCC 252 NM_003002.1
SDHD Exon 2 TGGTCTTAACTTCACAGTAACCCCA GGTCTTCATTTGACAAAGTTGGACA 413 NM_003002.1
SDHD Exon 3 TGTACACTGCCTGTCAGTTTGGG TAGGGCATTTCAATCAACTTCTCCC 345 NM_003002.1
SDHD Exon 4 GGAGACATTGCATTTGAACTTGACA AAAGCAGAGGCAAAGAGGCATACAT 334 NM_003002.1
LYRM4 TCGTACTTGGGACCTCGGCGAA TGGATGCTGAAGGTGGTCCCTG 379 NM_020408.3
Nfs1 fragment 1 TGCTCCTCAGTCTGCGGTT CCCCTTTGGGACCGTAGATT 686 NM_021100
Nfs1 fragment 2 TCCATACTGATGCAGCCCA CCAATCTAGAGCATCCACTAGG 789 NM_021100
Frataxin fragment 1 ACATCGATGCGACCTGCAC TGACACATAGCCCAACTGTCC 638 NM_181425.1
Frataxin fragment 2 GCAGAGGAAACGCTGGACT TGACACATAGCCCAACTGTCC 478 NM_181425.1
ALK fragment 1 GCTGGGTACCAAGGACTGTTCA CTGGTTCCTGAGGTCATGCAGT 957 CCDS37172.1
ALK fragment 2 AAGACTCCTTCCCTTTCCTGTCTC AAGGACACGTTTCCCCTCAAGA 949 CCDS37172.1
ALK fragment 3 GTTCCAGGACCACCAAGACCAT AAATACGTAGGTGGCTCCACCC 955 CCDS37172.1
ALK fragment 4 CCTGCCCCAGTACAAACCAGTT GCAGTAGTTGGGGTTGTAGTCGGT 947 CCDS37172.1
ALK fragment 5 CTGGCTTTCTCCGGCATCAT CCTGTCTTCAGGCTGATGTTGC 972 CCDS37172.1
ALK fragment 6 CTTGGATATATGCCATACCCCAGC GTTTGTGAAGGAGCCATTGCCT 970 CCDS37172.1
PHOX2B Exon1 CTCCAGCCACCTTCTCCATA TTCCTATATACGGGCGGAAA 369 NC_000004.11
PHOX2B Exon2 CAGCTTCTCTCGGCAACTCT GGCCCTAGGTCCTTCTCACT 426 NC_000004.11
PHOX2B Exon3 ACCCTAACCGGTGCTTTTCT ACAATAGCCTTGGGCCTACC 686 NC_000004.11
SDHAF1 CTGAGCGTCTCTGCTTAGCC CTCTGACATCCCCAATTCGT 506 NM_001042631.1
SDH5-fragment 1 GTTTCCGGTGCAGGTGGG GCACACAGTAGGCTCACCAA 251 NM_017841.1
SDH5-fragment 2 CCTGGCCACAGTGTAATTT TCAAATCAGCCTAAACTGTCCT 675 NM_017841.1
SDH5-fragment 3 GTGGTTCTTGGCCAGTGTTT GCAAGGCTAACGTCCATCAT 297 NM_017841.1
*SDHA fragment 1 was sequenced additionally with the following reverse primer: TCCGTCATGTAGTGGATGGC. bp: fragment length in base 
pairs. Ref-sequ.: GenBank-reference sequence.Feichtinger et al. BMC Cancer 2010, 10:149
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blocked 1 h at room temperature (RT) in 5% fat-free milk
powder dissolved in TBS. After washing with TBS- 0.1%
Tween 20, the membranes were incubated with the pri-
mary antibody solutions. Primary antibodies were diluted
in 5% fat-free milk powder dissolved in TBS. The follow-
ing primary antibody dilutions and incubation times were
used: monoclonal mouse anti-SDHA 70 kD antibody
(1:15 000, 2 h, RT); MitoSciences, Eugene, OR), monoclo-
nal mouse anti-Core 2 antibody (1:2000, 2 h, RT; MitoSci-
ences), polyclonal rabbit anti-GAPDH antibody (1:5000,
1 h, RT; Trevigen), polyclonal goat anti-VHL antibody
(1:10 000, overnight, 4°C; Everest). After washing, the
membranes were incubated with secondary antibodies as
follows: SDHA 70 kD and Core 2 blots, 2 h with poly-
clonal antimouse IgG POD-labeled antibody 1:400
[Lumi-LightPLUSWestern Blotting Kit (mouse/rabbit);
Roche] at RT; GAPDH 1 h with polyclonal anti-rabbit IgG
POD-labeled antibody 1:1000 [Lumi-LightPLUSWestern
Blotting Kit (mouse/rabbit); Roche] at RT; VHL 1 h with
polyclonal anti-goat IgG antibody 1:5000 (Dako,
Glostrup, Denmark) at RT. Detection was carried out
with Lumi-LightPLUSPOD substrate (Roche). After detec-
tion of SDHA 70 kD and Core 2 the nitrocellulose mem-
branes were washed twice in stripping buffer (25 mM
glycine-HCl, pH 2, 2% SDS) for 15 min, and a subsequent
immunodetection with GAPDH antibody was performed
as described above. Subsequently, the same stripping pro-
cedure was used prior to detection of VHL.
Immunohistochemical staining and analysis
Formalin-fixed and paraffin-embedded tumor tissues
were used. For immunohistochemical staining the follow-
ing antibodies were used: mouse monoclonal anti-com-
plex II subunit 70 kDa Fp (1:5000; MitoSciences), mouse
monoclonal anti-complex III subunit Core 2 (1:1500;
MitoSciences), and mouse monoclonal anti-porin 31HL
(1:3000; MitoSciences) antibodies. All antibodies were
diluted in Dako antibody diluent with background reduc-
ing components (Dako).
5 μm sections were deparaffinized and rehydrated, fol-
lowed by heat-induced epitope retrieval in TE-T buffer
(10 mM Tris base, pH 9.0, 1 mM EDTA, 0.05% Tween 20)
for 40 min at 95°C and 20 min at RT. Sections were
washed in distilled H2O and equilibrated with phosphate-
buffered saline containing 0.5% Tween 20 (pH 7.4, PBS-
T). Staining was performed using an Envision Detection
System (Dako) according to manufacturer's instructions,
followed by visualization with diaminobenzidine (DAB)
for 1 min. Slides were counterstained with hematoxylin.
Results
Characteristics of the 14 pediatric patients and their NB
tumors are given in Table 1. The activity of citrate syn-
thase was comparably high in normal cortical kidney tis-
sues and NBs (Figure 1). Moreover, the level of citrate
synthase activity was in accordance with the level of porin
as determined by immunohistochemical staining. Both
citrate synthase and porin are frequently used as marker
proteins for mitochondrial mass. The NBs showed only a
slight reduction of porin compared to normal adrenal
cortex and adrenal medulla tissue (Figure 2). Therefore,
the mitochondrial masses of the NBs and normal renal
tissues were similar.
As pheochromocytomas and NB originate from neural
crest and pheochromocytomas frequently show reduced
SDH activity caused by pathogenic SDH mutations, we
measured the enzymatic activity of SDH in NB. We
decided to compare OXPHOS enzyme activities of NB
with cortical kidney tissues since it is not possible to iso-
late a sufficient amount of foetal neural crest cells for
enzymatic measurements. In addition, the activity of cit-
ric synthase in NB tissues and normal kidney tissues does
not differ significantly. The NB samples (n = 14) showed a
mean residual SDH activity of 11 ± 12% compared to
u n a f f e c t e d  k i d n e y  c o r t e x  t i s s u e  ( n  =  1 4 )  ( F i g u r e .  1 ) .
Immunohistochemical staining of SDH in NB underlined
these results (Figure 2b, e, h).
T o evaluate if this massive downregulation of SDH in
N B  i s  d u e  t o  a  m u t a t i o n  i n  o n e  o f  t h e  f o u r  n u c l e a r -
encoded SDH subunits, we sequenced the SDH genes.
Sequencing of five NB samples did not reveal any patho-
genic mutation in the SDH genes. All SNPs were silent
mutations. The single nucleotide polymorphism (SNP)
rs1126417 was found in three of five NBs. Two of the five
NBs carried the SNP rs36097930. In addition, a new
nucleotide substitution, c.1948A>G p.Asn650Asp, was
detected in three NB samples in SDHA. The amino acid
residue shows only weak conservation, but has not been
published in the NCBI SNP database. The reference
sequences that were used for the alignment are listed in
Table 2. In addition no mutations in SDHAF1 and SDH5
were found (n = 14).
Because low SDH activity can be caused by downregu-
lation of iron-sulfur subunits [21,22] we also sequenced
nfs-1, LYRM4, frataxin (n = 7) for pathogenic mutations.
However, no sequence variations were found in compari-
son to the reference sequences.
To ensure that the neuroblastoma-predispostion genes
are not associated with the observed downregulation of
OXPHOS in our patients, ALK (n = 4) and PHOX2B (n =
14) was sequenced, but no pathogenic mutations were
detected.
Suppressed SDHB protein can be found in pheochro-
mocytomas with loss of VHL [19,36]. Immunoblotting
revealed that VHL protein was not reduced in NB tissues
compared to kidney tissues (Figure 3).
Because the investigated NBs had no pathogenic SDH
mutations and the amount of the VHL protein was unaf-Feichtinger et al. BMC Cancer 2010, 10:149
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fected, we evaluated the enzymatic activities of the other
OXPHOS complexes in comparison to normal kidney tis-
sue. All enzyme activities were significantly lower in NB
compared to kidney tissue (Table 3). Relative to citrate
synthase activity, we found mean residual activities of
complex I (23 ± 16%), complex III (74 ± 28%), complex IV
(COX) (28 ± 14%), and ATP synthase (20 ± 17%) in NB
tissues (Figure 1). There was no significant difference in
enzyme activities when correlated to ploidy or stage of
the NBs (data not shown).
Western blot analysis of SDH and complex III was in
agreement with the overall downregulation of OXPHOS
complexes in NB (Figure 3). In addition, immunohis-
tochemical analysis showed a reduction of complex II and
complex III in NB compared to unaffected adrenal cortex
and medulla (Figure 2).
The mtDNA copy number was significantly reduced in
NBs (n = 14) compared to cortical kidney tissues (n = 10)
(Figure 1g).
Discussion
NB showed a massive reduction in SDH activity com-
pared to normal cortical kidney tissues. Sequencing dem-
onstrated that the observed downregulation of SDH
activity is not due to pathogenic mutations in the genes
encoding the SDH subunits. These findings are in agree-
ment with previous studies which also failed to detect
pathogenic mutations in SDHB or SDHD [37,38]. SDHB
maps to chromosome 1p36, a region of frequent loss of
heterozygosity (LOH) in NB (Martinsson et al. 1997).
Astuti et al. (2004) could not provide evidence for epige-
netic inactivation of the SDHB  gene promoter [37].
Accordingly, our sample with a 1p36 deletion (patient 5,
Table 1) did not differ in OXPHOS activity compared to
the 1pdel negative samples.
Mutations in the assembly factors SDHAF1 and SDH5
could also be excluded to be the cause of the observed
phenotype. Furthermore, on the basis of our data the two
major NB predisposition genes can be excluded to lead to
the reduction of the OXPHOS enzyme activities in NBs.
Although NBs and pheochromocytomas share a common
origin, carcinogenesis in NBs is not linked to pathogenic
VHL mutations, as in a subset of pheochromocytomas
[39]. Deletions of the short arm of chromosome 3 are
often observed in a specific subset of aggressive NBs. The
critical deleted region encompasses the VHL locus. Hoe-
beeck et al. (2006) demonstrated that reduced VHL
mRNA expression is a poor prognostic indicator for NB.
The reduced expression of the VHL gene suggests that
VHL  could act in a haploinsufficient manner [40].
Because we detected no differences in the amount of
VHL protein between NB and normal kidney samples,
our data suggest that VHL is not involved in downregula-
tion of OXPHOS in the NB samples investigated.
Correct incorporation of the Fe-S cluster into SDH is a
prerequisite for the functionality of the SDH protein, and
downregulation of proteins involved in Fe-S cluster bio-
genesis could lead to diminished SDH activity. However,
we were not able to detect mutations in the Fe-S cluster
biogenesis genes frataxin, nfs-1 and LYRM4. Since
frataxin, nfs-1 and isd11 are only three proteins of the
ISC (iron sulfur cluster) machinery, it can not be
excluded that a mutation in one of the other proteins
involved in ISC biogenesis is responsible for the massive
impairment of the SDH activity in NB.
Alterations of ISC proteins also lead to a reduction of
complexes I and III. The measurements of the enzymatic
activities of complex I, complex III, complex IV and ATP
synthase indicate an overall downregulation of the aero-
bic energy metabolism in NB. Because complex IV and
complex V possess no Fe-S clusters, the reduction of
complex IV and complex V activity can not be related to a
defect of an ISC assembly protein.
The significant reduction of the mtDNA copy number
in NBs could explain a reduction of OXPHOS complexes
with exception of SDH, which is nuclear encoded. There-
fore, the phenotype from NBs differs from that in classi-
Figure 1 Activity of OXPHOS complexes in normal kidney tissues 
and NBs. a: citrate synthase (CS), b: complex I (CI), c: complex II (CII), d: 
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cal depletion syndromes where high SDH activities can
be detected.
The observed overall reduction of activity of the
enzymes of the OXPHOS system is not due to downregu-
lation of mitochondrial mass, because measurement of
citrate synthase and staining of porin revealed that NBs
and control kidney samples possess equal amounts of
mitochondria. We have used normal kidney as a refer-
ence because this tissue has comparable citrate synthase
activity to NBs. In order to conclude that NB tumor cells
have downregulated OXPHOS components, the cell type
from which the tumor originates has to be analyzed.
Because we were not able to get enough normal adrenal
tissue for enzymatic analysis, we performed an immuno-
histochemical analysis on normal adrenal tissue and were
able to show that cells of the adrenal cortex and medulla
did indeed have substantial staining of porin, complex II
and complex III. This indicates clearly the loss of
OXPHOS during tumor transformation and progression.
We are aware of the limitation of the comparison of NBs
to adjacent adrenal tissue since NBs are derived from pri-
mordial neural crest cells which can not be detected in
postnatal adrenal cortex and medulla.
Conclusion
In summary the molecular mechanisms leading to
OXPHOS impairment in pheochromocytomas and neu-
roblastomas differ between these two tumor entities. In
Figure 2 Immunohistochemical staining of porin, complex II and complex III of NB, adjacent adrenal cortex and adrenal medulla. Immuno-
histochemical staining of porin (a, d, g), complex II subunit 70 kDa Fp (b, e, h) and complex III subunit Core2 (c, f, i) in unaffected adrenal tissue (a, b, c) 




Figure 3 Western blot analysis of NBs and kidney tissue samples. 
Complex II (SDHA; subunit 70 kDa Fp), Complex III (subunit Core 2), 
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NB there are no pathogenic mutations in SDH subunits
present and there is not a single enzyme deficiency, but
there is downregulation of all components of the aerobic
mitochondrial energy metabolism without affecting
mitochondrial mass.
Knowledge of the mechanism of tumor cells to achieve
the Warburg effect provides the basics for functional
studies to recover the aerobic energy metabolism as a
potential new therapeutic strategy to threat malignancies.
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